Nebenwirkungen · Pegasys
Pegasys 180 micrograms solution for injection · Abschnitt 4.8 · PDF-Seite 60–61
HOS-109900 · Präparat HOS-093265
60 Laboratory values for HIV-HCV co-infected patients Although haematological toxicities of neutropenia, thrombocytopenia and anaemia occurred more frequently in HIV-HCV patients, the majority could be managed by dose modification and the use of growth factors and infrequently required premature discontinuation of treatment. Decrease in ANC levels below 500 cells/mm3 was observed in 13% and 11% of patients receiving Pegasys monotherapy and combination therapy, respectively. Decrease in platelets below 50 000 cells/mm3 was observed in 10% and 8% of patients receiving Pegasys monotherapy and combination therapy, respectively. Anaemia (haemoglobin < 10 g/dL) was reported in 7% and 14% of patients treated with Pegasys monotherapy or in combination therapy, respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T12:00:00Z · SHA-256 d1a2dc533bd5ba4d4a21ad6973e4498c4ffde781c784ae67bbeeda36922e6382 · Passage c0514afe3314b4817ee9c256b888ad77d356f624956ba038aecc21eb8b463df1 · Zeichen 16481–17258 im Abschnitt